抗蜱传脑炎病毒嵌合抗体。
Chimeric antibodies against tick-borne encephalitis virus.
机构信息
Federal State Research Institution State Research Center of Virology and Biotechnology Vector, Koltsovo, Novosibirsk Region 630559, Russia.
出版信息
Vaccine. 2010 Jul 19;28(32):5265-71. doi: 10.1016/j.vaccine.2010.05.060. Epub 2010 Jun 9.
Two chimeric antibodies (ch) 13D6 and 10C2 against the glycoprotein E of tick-borne encephalitis virus (TBEV) were constructed by fusing variable regions of murine monoclonal antibodies (Mabs) 13D6 and 10C2 to human constant regions. Monovalent analogues of these antibodies in format of single-chain antibodies (scFv or sc) were developed, as well. The ch13D6, ch10C2, sc13D6 and sc10C2 exhibited binding characteristics similar to parental Mabs. Only the ch13D6 and sc13D6 were able to neutralize TBEV infectivity in vitro. The in vitro neutralization provided by ch13D6 suggests that this antibody can be further developed into a potent prophylaxis and therapy for tick-borne encephalitis (TBE) infection.
两种嵌合抗体（ch）13D6 和 10C2 针对蜱传脑炎病毒（TBEV）的糖蛋白 E 构建，方法是将鼠单克隆抗体（Mab）13D6 和 10C2 的可变区融合到人恒定区。这些抗体的单价类似物也以单链抗体（scFv 或 sc）的形式开发。ch13D6、ch10C2、sc13D6 和 sc10C2 表现出与亲本 Mab 相似的结合特性。只有 ch13D6 和 sc13D6 能够在体外中和 TBEV 感染性。ch13D6 提供的体外中和作用表明，该抗体可进一步开发为针对蜱传脑炎（TBE）感染的有效预防和治疗方法。
Zotero 插件